Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 12/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133128 | 0.85 | PKM (0.56) | PKMEPHX1HTTALDH1A1EPHX2 | |
| SCHEMBL4127191 | 0.82 | CTSK (0.43) | PKMALDH1A1 | |
| SCHEMBL1863235 | 0.77 | CTSK (0.44) | — | |
| SCHEMBL4139158 | 0.75 | CTSK (0.45) | PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL5014244 | 0.74 | EPHX1 (0.48) | PKMEPHX1HTTALDH1A1EPHX2 | |
| SCHEMBL1982137 | 0.73 | TAAR1 (0.50) | EPHX1HTTALDH1A1EPHX2SMN1; SMN2 | |
| SCHEMBL6360441 | 0.73 | MEN1 (0.44) | HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL11033138 | 0.73 | EPHX1 (0.84) | EPHX1HTTALDH1A1EPHX2HDAC1 | |
| SCHEMBL11034317 | 0.73 | EPHX1 (0.84) | EPHX1HTTALDH1A1EPHX2HDAC1 | |
| SCHEMBL6438783 | 0.73 | EPHX1 (0.84) | EPHX1HTTALDH1A1EPHX2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | PKM 4493/4885EPHX1 4403/4885HTT 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.